Dr Pavlakis said the team contributed to the new guidelines by drawing on its expertise in nuclear medicine, systemic therapies, surgery, interventional radiology and clinical trial experience.
“We are confident the new guidelines will provide tremendously valuable, evidenced-based information in a format which is easy to access and adopt,” he said.
In recent years, Sydney Theranostics North – based at RNSH was named a Neuroendocrine Tumour Centre of Excellence, one of just three centres in the southern hemisphere.
Dr Chan said the accreditation is a testament to the exceptional team of clinicians, surgeons, nurses, allied health professionals and researchers at RNSH.
“It’s a credit to a very large number of teams, from medical oncology, radiology and surgery to genetics, palliative care and nutrition,” he said.
To access the new guidelines for the treatment of neuroendocrine tumours:
https://app.magicapp.org/#/guideline/7724